{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:11Z","timestamp":1780038131600,"version":"3.53.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant therapy improves local control and tumor downstaging in locally advanced rectal cancer (LARC) and is now the standard of care. However, reliable tools for identifying patients who may show different response patterns to neoadjuvant immunotherapy-containing treatment, particularly MRI-based risk stratification systems, remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective study included 135 patients with locally advanced rectal cancer, who were classified into a neoadjuvant immunotherapy plus chemoradiotherapy group (nICRT, n = 43) and a neoadjuvant chemoradiotherapy group (nCRT, n = 92). The nICRT group received short-course radiotherapy plus CAPOX and sintilimab, whereas the nCRT group received either short-course radiotherapy plus CAPOX or long-course chemoradiotherapy plus CAPOX. All patients underwent baseline pelvic MRI, including high-resolution T2-weighted, diffusion-weighted, and T1-weighted sequences. Evaluated variables included mrT stage, mrN stage, mrEMVI status, mrMRF involvement, tumor length, and clinical laboratory indices. Interobserver agreement was assessed using Cohen\u2019s kappa statistics, and factors associated with pathological complete response (pCR) were analyzed using group comparisons and logistic regression analyses. Fisher\u2019s exact test was used for subgroup comparisons. Receiver operating characteristic analysis was performed to evaluate predictive performance, and bootstrap resampling was used for internal validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An MRI-based assessment using mrEMVI, mrMRF, and tumor length \u2265 5\u00a0cm yielded a three-factor risk score that predicted pCR with an AUC of 0.835. In the MRI high-risk group (2\u20133 points), pCR rates were higher with nICRT than with nCRT (7\/19, 36.8% vs. 7\/60, 11.7%, P\u00a0=\u00a00.033), whereas in the low-risk group (0\u20131 points) the difference was not significant (19\/24, 79.2% vs. 21\/32, 65.6%, P\u00a0=\u00a00.373). In a sensitivity analysis restricted to the short-course SPRING-01 cohort, the direction of the association remained similar, although statistical significance was not retained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In MRI-defined high-risk patients, nICRT was associated with a higher pCR rate than nCRT. These findings suggest that pretreatment MRI-based stratification may help identify clinically relevant subgroups with different response patterns to intensified neoadjuvant treatment. However, the results should be considered exploratory and require prospective validation before clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1782231","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:08:54Z","timestamp":1780034934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiali","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]},{"name":"Shandong First Medical University (Shandong Academy of Medical Sciences)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]},{"name":"Shandong First Medical University (Shandong Academy of Medical Sciences)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghai","family":"Dai","sequence":"additional","affiliation":[{"name":"Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Xin","sequence":"additional","affiliation":[{"name":"Magnetic Resonance (MR) Research Collaboration, Siemens Healthineers Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1619043","article-title":"Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study","volume":"16","author":"Fan","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00286-4","article-title":"Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine\u2013oxaliplatin versus short-course radiotherapy followed by capecitabine\u2013oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial","volume":"26","author":"Tian","year":"2025","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1470-2045(22)00214-5","article-title":"Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study","volume":"23","author":"Lord","year":"2022","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5917","article-title":"Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer","volume":"95","author":"Smith","year":"2008","journal-title":"J Br Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-021-01023-4","article-title":"MRI-detected extramural venous invasion of rectal cancer: multimodality performance and implications at baseline imaging and after neoadjuvant therapy","volume":"12","author":"Inoue","year":"2021","journal-title":"Insights into Imaging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-017-5026-2","article-title":"Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting","volume":"28","author":"Beets-Tan","year":"2018","journal-title":"Eur Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004499","article-title":"MRI-diagnosed tumor deposits and EMVI status have superior prognostic accuracy to current clinical TNM staging in rectal cancer","volume":"276","author":"Lord","year":"2022","journal-title":"Ann Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1125470","article-title":"Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: an analysis of 124 patients","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i48.5310","article-title":"Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer","volume":"17","author":"Park","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7251","article-title":"A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer","volume":"13","author":"Wang","year":"2024","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1049228","article-title":"Active surveillance in long period of total neoadjuvant therapy in rectal cancer: early prediction of poor regression response","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2024.07.015","article-title":"Evaluating complete response rates and predictors in total neoadjuvant therapy for rectal cancer","volume":"28","author":"Erozkan","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers13010016","article-title":"A comprehensive evaluation of associations between routinely collected staging information and the response to (chemo)radiotherapy in rectal cancer","volume":"13","author":"Hammarstr\u00f6m","year":"2020","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-013-1821-7","article-title":"Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer","volume":"29","author":"Garland","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12212-w","article-title":"Molecular basis of extramural vascular invasion (EMVI) in colorectal carcinoma","volume":"29","author":"Sonal","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.03.006","article-title":"Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer","volume":"111","author":"Buijsen","year":"2014","journal-title":"Radiother Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s12885-018-5022-1","article-title":"Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients","volume":"18","author":"Belluco","year":"2018","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7225","article-title":"The association of preoperative hematologic parameters with short\u2010term clinical outcomes in rectal cancer: a feature importance analysis","volume":"13","author":"Orafaie","year":"2024","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s12029-018-0173-5","article-title":"Platelet and neutrophil counts as predictive markers of neoadjuvant therapy efficacy in rectal cancer","volume":"50","author":"Policicchio","year":"2019","journal-title":"J Gastrointest Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916840","article-title":"Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:08:55Z","timestamp":1780034935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1782231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1782231"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1782231","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1782231"}}